Compendium of Cancer Genome Aberrations

STBT5:Volunteer Assignments and Opportunities: Difference between revisions

[checked revision][checked revision]
← Older edit
VisualWikitext
No edit summary
No edit summary
 
(9 intermediate revisions by 4 users not shown)
Line 6: Line 6:


To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.<br />
To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.<br />
__TOC__
{| class="wikitable" style="margin:auto"
{| class="wikitable" style="margin:auto"
|+<big>WHO Classification of Soft Tissue and Bone Tumours (5th edition) Content</big>
|+<big>WHO Classification of Soft Tissue and Bone Tumours (5th edition) Content</big>
Line 17: Line 18:
!'''Notes'''
!'''Notes'''
|-
|-
|CHAPTER 2 (SOFT TISSUE TUMOURS)
|
====CHAPTER 2 (SOFT TISSUE TUMOURS)====
|
|
----
----
Line 146: Line 148:
|
|
|
|
|-
|-
!'''Disease'''!!'''Page Type'''!!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[STBT5:Atypical_lipomatous_tumour_/_well-differentiated_liposarcoma|Atypical lipomatous tumour / well-differentiated liposarcoma]]
|[[STBT5:Atypical_lipomatous_tumour_/_well-differentiated_liposarcoma|Atypical lipomatous tumour / well-differentiated liposarcoma]]
Line 256: Line 267:
|
|
|
|
|-
|-
!'''Disease'''!!'''Page Type'''!!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[STBT5:Fibrous_hamartoma_of_infancy|Fibrous hamartoma of infancy]]
|[[STBT5:Fibrous_hamartoma_of_infancy|Fibrous hamartoma of infancy]]
Line 366: Line 386:
|
|
|
|
|-
|-
!'''Disease'''!!'''Page Type'''!!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[STBT5:Cellular_angiofibroma|Cellular angiofibroma]]
|[[STBT5:Cellular_angiofibroma|Cellular angiofibroma]]
Line 477: Line 506:
|
|
|-
|-
|[[STBT5:Solitary_fibrous_tumour|Solitary fibrous tumour]]
|-
!'''Disease'''!!'''Page Type'''!!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|[[STBT5:Solitary_fibrous_tumour|Solitary fibrous tumour]]
|Disease
|Disease
|Shashi Shetty and Reba Daniel (resident)
|Shashi Shetty and Reba Daniel (resident)
Line 534: Line 572:
|[[STBT5:Infantile_fibrosarcoma|Infantile fibrosarcoma]]
|[[STBT5:Infantile_fibrosarcoma|Infantile fibrosarcoma]]
|Disease
|Disease
|
|Katie Schieffer
|
|4/21/2025
|
|10/1/2025
|
|PENDING
|
|
|
|
Line 586: Line 624:
|
|
|
|
|-
|-
!'''Disease'''!!'''Page Type'''!!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[STBT5:Tenosynovial_giant_cell_tumour|Tenosynovial giant cell tumour]]
|[[STBT5:Tenosynovial_giant_cell_tumour|Tenosynovial giant cell tumour]]
Line 696: Line 743:
|
|
|
|
|-
|-
!'''Disease'''!!'''Page Type'''!!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[STBT5:Lymphangioma_and_lymphangiomatosis|Lymphangioma and lymphangiomatosis]]
|[[STBT5:Lymphangioma_and_lymphangiomatosis|Lymphangioma and lymphangiomatosis]]
Line 806: Line 862:
|
|
|
|
|-
|-
!'''Disease'''!!'''Page Type'''!!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[STBT5:Myopericytoma,_including_myofibroma|Myopericytoma, including myofibroma]]
|[[STBT5:Myopericytoma,_including_myofibroma|Myopericytoma, including myofibroma]]
Line 916: Line 981:
|
|
|
|
|-
|-
!'''Disease'''!!'''Page Type'''!!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[STBT5:Spindle_cell_/_sclerosing_rhabdomyosarcoma|Spindle cell / sclerosing rhabdomyosarcoma]]
|[[STBT5:Spindle_cell_/_sclerosing_rhabdomyosarcoma|Spindle cell / sclerosing rhabdomyosarcoma]]
Line 1,026: Line 1,100:
|
|
|
|
|-
|-
!'''Disease'''!!'''Page Type'''!!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[STBT5:Solitary_circumscribed_neuroma|Solitary circumscribed neuroma]]
|[[STBT5:Solitary_circumscribed_neuroma|Solitary circumscribed neuroma]]
Line 1,137: Line 1,220:
|
|
|-
|-
|[[STBT5:Angiomatoid_fibrous_histiocytoma|Angiomatoid fibrous histiocytoma]]
|-
|Disease
!'''Disease'''!!'''Page Type'''!!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|[[STBT5:Angiomatoid_fibrous_histiocytoma|Angiomatoid fibrous histiocytoma]]
|Disease
|
|
|
|
Line 1,207: Line 1,299:
|James Solomon, MD, PhD
|James Solomon, MD, PhD
|2/20/2022
|2/20/2022
|
|12/9/2025
|PENDING
|PENDING
|
|
|Alanna Church
|Katie Schieffer
|
|
|
|
Line 1,257: Line 1,349:
|
|
|
|
|-
|-
!'''Disease'''!!'''Page Type'''!!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[STBT5:Extraskeletal_myxoid_chondrosarcoma_|Extraskeletal myxoid chondrosarcoma]]
|[[STBT5:Extraskeletal_myxoid_chondrosarcoma_|Extraskeletal myxoid chondrosarcoma]]
Line 1,324: Line 1,425:
|
|
|-
|-
|CHAPTER 3 (UNDIFFERENTIATED SMALL ROUND CELL SARCOMAS OF BONE AND SOFT TISSUE)
|
====CHAPTER 3 (UNDIFFERENTIATED SMALL ROUND CELL SARCOMAS OF BONE AND SOFT TISSUE)====
|
|
----
----
Line 1,348: Line 1,450:
|Sadeem Qdaisat
|Sadeem Qdaisat
|10/1/23
|10/1/23
|
|12/9/2025
|PENDING
|PENDING
|
|
Line 1,368: Line 1,470:
|[[STBT5:CIC-rearranged_sarcoma|CIC-rearranged sarcoma]]
|[[STBT5:CIC-rearranged_sarcoma|CIC-rearranged sarcoma]]
|Disease
|Disease
|Ganesh Pandurang, MD
|2/28/24
|
|
|PENDING
|
|
|
|Katherine Geiersbach
|
|
|
|
|
|
|
Line 1,388: Line 1,490:
|
|
|-
|-
|CHAPTER 4 (BONE TUMOURS)
|-
|
!'''Disease'''!!'''Page Type'''!!'''<span style="color:#0070C0">Author'''
----
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|
====CHAPTER 4 (BONE TUMOURS)====
|
----
|
|
----
----
Line 1,528: Line 1,640:
|
|
|
|
|-
|-
!'''Disease'''!!'''Page Type'''!!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[STBT5:Central_chondrosarcoma,_grades_2_and_3|Central chondrosarcoma, grades 2 and 3]]
|[[STBT5:Central_chondrosarcoma,_grades_2_and_3|Central chondrosarcoma, grades 2 and 3]]
Line 1,638: Line 1,759:
|
|
|
|
|-
|-
!'''Disease'''!!'''Page Type'''!!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[STBT5:Osteosarcoma|Osteosarcoma]]
|[[STBT5:Osteosarcoma|Osteosarcoma]]
Line 1,749: Line 1,879:
|
|
|-
|-
|[[STBT5:Angiosarcoma_of_bone|Angiosarcoma of bone]]
|-
!'''Disease'''!!'''Page Type'''!!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|[[STBT5:Angiosarcoma_of_bone|Angiosarcoma of bone]]
|Disease
|Disease
|
|
Line 1,858: Line 1,997:
|
|
|
|
|-
|-
!'''Disease'''!!'''Page Type'''!!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[STBT5:Adamantinoma_of_long_bones|Adamantinoma of long bones]]
|[[STBT5:Adamantinoma_of_long_bones|Adamantinoma of long bones]]
Line 1,968: Line 2,116:
|
|
|
|
|-
|-
!'''Disease'''!!'''Page Type'''!!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[STBT5:Langerhans_cell_histiocytosis_|Langerhans cell histiocytosis]]
|[[STBT5:Langerhans_cell_histiocytosis_|Langerhans cell histiocytosis]]
Line 2,002: Line 2,159:
|
|
|-
|-
|CHAPTER 5 (GENETIC TUMOUR SYNDROMES OF SOFT TISSUE AND BONE)
|
====CHAPTER 5 (GENETIC TUMOUR SYNDROMES OF SOFT TISSUE AND BONE)====
|
|
----
----
Line 2,035: Line 2,193:
|[[STBT5:Li-Fraumeni_syndrome|Li-Fraumeni syndrome]]
|[[STBT5:Li-Fraumeni_syndrome|Li-Fraumeni syndrome]]
|Disease
|Disease
|
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|-
|-
|[[STBT5:McCune-Albright_syndrome|McCune-Albright syndrome]]
|[[STBT5:McCune-Albright_syndrome|McCune-Albright syndrome]]
Line 2,068: Line 2,226:
|[[STBT5:Neurofibromatosis_type_1|Neurofibromatosis type 1]]
|[[STBT5:Neurofibromatosis_type_1|Neurofibromatosis type 1]]
|Disease
|Disease
|
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|-
|-
|[[STBT5:Rothmund-Thomson_syndrome|Rothmund-Thomson syndrome]]
|[[STBT5:Rothmund-Thomson_syndrome|Rothmund-Thomson syndrome]]
Retrieved from "https://test.ccga.io/index.php/STBT5:Volunteer_Assignments_and_Opportunities"